BiotechTube

Raloxifene HCL + Raloxifene HCL + Placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Osteoporosis, Postmenopausal

Conditions

Osteoporosis, Postmenopausal

Trial Timeline

Nov 1, 1994 → Sep 1, 1999

NCT ID
NCT00670319

About Raloxifene HCL + Raloxifene HCL + Placebo

Raloxifene HCL + Raloxifene HCL + Placebo is a phase 3 stage product being developed by Eli Lilly for Osteoporosis, Postmenopausal. The current trial status is completed. This product is registered under clinical trial identifier NCT00670319. Target conditions include Osteoporosis, Postmenopausal.

What happened to similar drugs?

20 of 20 similar drugs in Osteoporosis, Postmenopausal were approved

Approved (20) Terminated (0) Active (0)
✅raloxifene + PlaceboEli LillyApproved
✅raloxifene + placeboEli LillyApproved
✅MENATETRANONEEisaiApproved
✅Menatetrenone (Vitamin K2)EisaiApproved
✅teriparatideEli LillyApproved
✅Teriparatide + Aspara-CA 600 mg + Alfarol 1.0 µgEli LillyApproved
✅Teriparatide + Strontium ranelateEli LillyApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00670319Phase 3Completed

Competing Products

20 competing products in Osteoporosis, Postmenopausal

See all competitors
ProductCompanyStageHype Score
ENZ215 + ProliaAlkem LaboratoriesPhase 3
40
Teriparatide + Alendronate Sodium + Placebo + PlaceboEli LillyPhase 3
40
TeriparatideEli LillyPhase 3
40
teriparatide + teriparatide + Placebo + Calcium Supplement + Vitamin D SupplementEli LillyPhase 3
40
raloxifene + PlaceboEli LillyApproved
43
Subcutaneous Teriparatide + Transdermal TeriparatideEli LillyPhase 2
35
teriparatide 20 micrograms/day subcutaneous + calcitonin 100 IU/day subcutaneousEli LillyPhase 3
40
raloxifene + placeboEli LillyApproved
43
Teriparatide + Salmon CalcitoninEli LillyPhase 3
40
ForteoEli LillyPre-clinical
22
arzoxifene + PlaceboEli LillyPhase 2
35
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
40
CT-P41 + US-licensed ProliaCelltrionPhase 3
40
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboChugai PharmaceuticalPhase 3
40
Eldecalcitol soft capsulesChugai PharmaceuticalPre-clinical
22
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RISChugai PharmaceuticalPhase 3
40
Denosumab + Placebo + Alendronate sodium hydrateDaiichi SankyoPhase 3
40
YM529 / ONO-5920Astellas PharmaPhase 2/3
38
ONO-5920Astellas PharmaPhase 3
40
Minodronic acid hydrateAstellas PharmaPhase 3
40